^
Association details:
| Biomarker: | RAD51B promoter methylation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer
Published date:
04/08/2020
Excerpt:
...type of anti-PD-1 treatment (nivolumab, pembrolizumab, according to the current practice at the time)....Table 3. RAD51Bme, PD-L1 staining and the combination of the two variables performances as predictive biomarkers of PD-1 blockade response in the Treated Cohort (#2)....PD-L1+ and RAD51Bme+ are promising biomarkers to predict response to PD-1 blockade rather than overall prognostic factors in NSCLC’s patients.
